These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 8907820)

  • 21. Adjuvant endocrine therapy for early breast cancer.
    Andreetta C; Smith I
    Cancer Lett; 2007 Jun; 251(1):17-27. PubMed ID: 17150303
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dissemination of adjuvant multiagent chemotherapy and tamoxifen for breast cancer in the United States using estrogen receptor information: 1975-1999.
    Mariotto AB; Feuer EJ; Harlan LC; Abrams J
    J Natl Cancer Inst Monogr; 2006; (36):7-15. PubMed ID: 17032888
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Incidence and management of side effects associated with aromatase inhibitors in the adjuvant treatment of breast cancer in postmenopausal women.
    Mouridsen HT
    Curr Med Res Opin; 2006 Aug; 22(8):1609-21. PubMed ID: 16870085
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Effectiveness of adjuvant systemic therapy in organ preserving treatment of pT1-2N0M0 breast cancer].
    Semiglazov VF; Kanaev SV; Bugrova IL; Vlasov AN
    Vopr Onkol; 1999; 45(5):516-9. PubMed ID: 10629708
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adjuvant hormonal therapy for premenopausal women with breast cancer.
    Brown RJ; Davidson NE
    Semin Oncol; 2006 Dec; 33(6):657-63. PubMed ID: 17145345
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adjuvant therapy for breast cancer.
    NIH Consens Statement; 2000 Nov 1-3; 17(4):1-35. PubMed ID: 11512506
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Systemic adjuvant therapy of breast cancer.
    O'Connell J
    Conn Med; 1999 Jan; 63(1):29-33. PubMed ID: 10071436
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Defining the role of aromatase inhibitors in the adjuvant endocrine treatment of early breast cancer.
    Buzdar A; Chlebowski R; Cuzick J; Duffy S; Forbes J; Jonat W; Ravdin P
    Curr Med Res Opin; 2006 Aug; 22(8):1575-85. PubMed ID: 16870082
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Systemic adjuvant therapy of breast cancer: myths and controversies].
    Roy JA; Piccart MJ
    Rev Med Brux; 1996 Sep; 17(4):267-70. PubMed ID: 8927859
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The 76-gene signature defines high-risk patients that benefit from adjuvant tamoxifen therapy.
    Zhang Y; Sieuwerts AM; McGreevy M; Casey G; Cufer T; Paradiso A; Harbeck N; Span PN; Hicks DG; Crowe J; Tubbs RR; Budd GT; Lyons J; Sweep FC; Schmitt M; Schittulli F; Golouh R; Talantov D; Wang Y; Foekens JA
    Breast Cancer Res Treat; 2009 Jul; 116(2):303-9. PubMed ID: 18821012
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Adjuvant for breast cancer chemo-endocrine therapy].
    Taguchi T
    Gan To Kagaku Ryoho; 1998 Mar; 25(4):453-67. PubMed ID: 9530350
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of adjuvant systemic treatment on cosmetic outcome and late normal-tissue reactions after breast conservation.
    Johansen J; Overgaard J; Overgaard M
    Acta Oncol; 2007; 46(4):525-33. PubMed ID: 17497320
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer.
    Berns EM; Foekens JA; Vossen R; Look MP; Devilee P; Henzen-Logmans SC; van Staveren IL; van Putten WL; Inganäs M; Meijer-van Gelder ME; Cornelisse C; Claassen CJ; Portengen H; Bakker B; Klijn JG
    Cancer Res; 2000 Apr; 60(8):2155-62. PubMed ID: 10786679
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tamoxifen versus control after adjuvant, risk-adapted chemotherapy in postmenopausal, receptor-negative patients with breast cancer: a randomized trial (GABG-IV D-93)--the German Adjuvant Breast Cancer Group.
    Kaufmann M; Graf E; Jonat W; Eiermann W; Geberth M; Albert US; Gademann G; Conrad B; Stahl K; von Minckwitz G; Schumacher M;
    J Clin Oncol; 2005 Nov; 23(31):7842-8. PubMed ID: 16258087
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Current trends in pharmacotherapy of breast cancer].
    Boér K
    Orv Hetil; 2002 Apr; 143(14):725-30. PubMed ID: 11975393
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical practice guidelines for the care and treatment of breast cancer: adjuvant systemic therapy for node-negative breast cancer (summary of the 2001 update).
    Levine M;
    CMAJ; 2001 Jan; 164(2):213. PubMed ID: 11332317
    [No Abstract]   [Full Text] [Related]  

  • 37. Tamoxifen treatment after adjuvant chemotherapy has opposite effects on bone mineral density in premenopausal patients depending on menstrual status.
    Vehmanen L; Elomaa I; Blomqvist C; Saarto T
    J Clin Oncol; 2006 Feb; 24(4):675-80. PubMed ID: 16446340
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Estimating the benefits of adjuvant systemic therapy for women with early breast cancer.
    Grogan M; Tabar L; Chua B; Chen HH; Boyages J
    Br J Surg; 2001 Nov; 88(11):1513-8. PubMed ID: 11683751
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of goserelin in the treatment of breast cancer.
    Rody A; Loibl S; von Minckwitz G; Kaufmann M
    Expert Rev Anticancer Ther; 2005 Aug; 5(4):591-604. PubMed ID: 16111461
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Adjuvant therapy of breast cancer].
    Semiglazov VF; Abzumanov AS; Bozhok AA; Ivanov VG; Ivanova OA; Barash NIu; Topuzov EE; Seleznev IK; Migmanova NSh; Popova RT; Nurgaziev KSh
    Khirurgiia (Mosk); 2001; (5):52-60. PubMed ID: 11505673
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.